Sickle-cell disease is characterized by painful vaso-occlusive crises during which abnormal interactions between erythroid adhesion molecules and vessel-wall proteins are thought to play a critical role. Hydroxyurea, the only drug with proven benefit in sickle-cell disease, diminishes these interactions but its mechanism of action is not fully understood. We report that, under hydroxyurea, expression of the unique erythroid laminin receptor Lu/BCAM was increased but red blood cell adhesion to laminin decreased. Because Lu/BCAM phosphorylation is known to activate cell adhesion to laminin, it was evaluated and found to be dramatically lower in hydroxyurea-treated patients. Analysis of the protein kinase A pathway showed decreased intracellular levels of the upstream effector cAMP during hydroxyurea treatment. Using a cellular model expressing recombinant Lu/BCAM, we showed that hydroxyurea led to decreased intracellular cAMP levels and diminished Lu/BCAM phosphorylation and cell adhesion. We provide evidence that hydroxyurea could reduce abnormal sickle red blood cell adhesion to the vascular wall by regulating the activation state of adhesion molecules independently of their expression level.
Introduction
Sickle-cell disease (SCD) is characterized by painful episodic vaso-occlusive crises (VOC), acute chest syndrome and a chronic inflammatory state. Hydroxyurea (HU), also called hydroxycarbamide, is the only drug now available having demonstrated benefit for SCD patients, with fewer VOC and acute chest syndromes, and lower mortality and morbidity. [1] [2] [3] [4] It was commonly thought that HU acted as an anti-sickling agent by increasing fetal hemoglobin (HbF) levels, leading to significantly less hemoglobin S polymerization. However, HU was often associated with clinical improvement before HbF rose significantly, suggesting that it could also act through other mechanisms. 2 Growing evidence supports the hypothesis that, in SCD patients, transit of red blood cells fibronectin, thrombospondin (TSP) and endothelial Lu/BCAM (Lutheran/basal cell-adhesion molecule). [8] [9] [10] [11] [12] [13] TSP mediates adhesion of SS reticulocytes to endothelial cells by bridging CD36
molecules expressed on both cell types. 14 However, the clinical severity of SCD in CD36-deficient patients is not diminished. 15 Landsteiner-Wiener/intercellular adhesion molecule-4
(LW/ICAM-4) and Lu/BCAM are members of the immunoglobulin superfamily, expressed on young and mature RBCs; they are also involved in the abnormal adhesion of SS RBCs through
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interactions with endothelial integrin α V β 3 and ECM laminin 511/521, respectively. [16] [17] [18] [19] [20] [21] In vivo, HU decreases the percentage of circulating CD36-and α 4β1-expressing reticulocytes 22 and CD36 and α 4 β 1 expression levels at the mRNA and protein levels; 23 it also reduces phosphatidylserine expression on the surfaces of erythrocytes and platelets, 24 and plasma levels of soluble VCAM-1 and endothelin-1. 25, 26 HU diminishes SS RBC adhesion to endothelial cells and the ECM proteins, fibronectin, TSP and laminin. 23, 27, 28 These decreases are consistent with less CD36, α 4 β 1 and LW/ICAM-4 expression on the surfaces of SS reticulocytes and erythrocytes. 29 Surprisingly, Odièvre et al showed that RBC expression of Lu/BCAM, the unique erythroid receptor for laminin, 19, 21 was significantly elevated in HU-treated children. 29 Consequently, SS RBC adhesion to laminin could not be directly linked to the cell-surface Lu/BCAM expression level. Lu/BCAM is responsible for abnormal SS RBC adhesion to laminin in a protein-kinase A (PKA)-and/or Rap1-dependent manner. 30, 31 Although Lu/BCAM is expressed on normal (AA) and SS RBCs, only SS RBCs adhere to laminin and resist high shearstress forces. 19, 21, 32 This adhesion is activated by the phosphorylation of serine 621 in the Lu/BCAM cytoplasmic domain upon PKA-pathway activation. 33 
Cell lines and antibodies
Human erythroleukemic K562 cells expressing the long human Lu/BCAM isoform (Lu gp), K562-Lu, were obtained and grown, in the absence or presence of 250 µM HU (Sigma-Aldrich, Saint-Quentin Fallavier, France) for 24 and 48 hours, 27 as described. 19 Mouse anti-human Lu/BCAM monoclonal antibody (mAb), clone F241, was produced in our institute. 33 Biotinylated goat polyclonal anti-Lu/BCAM antibody was from R&D Systems (Minneapolis, MN).
Flow cytometry
Percentages of reticulocytes in whole or fractionated blood samples were determined using 
Percoll double-density separation
All collected blood samples designated for this fractionation were kept at 4°C overnight, then subjected to density separation at room temperature as described. 35 Percoll (Sigma-Aldrich) was diluted in 125 mM NaCl, 4.5 mM KCl, 3% bovine serum albumin (BSA) to obtain densities of 1.076 and 1.085; 3 ml of the latter density were placed in an empty 15-ml polypropylene tube followed by 3 ml of the former, then 3 ml of whole blood were carefully loaded onto the surface.
After centrifugation (30 min, 1000×g), blood fractions were collected and washed 3 times with
Hanks' buffer (Sigma-Aldrich). An aliquot was saved to count reticulocytes by flow cytometry and the rest was used in adhesion and phosphorylation assays.
Adhesion assays
RBC and K562-Lu-cell adhesions to laminin were measured under physiological flow conditions using a plate flow chamber, by a person blinded to the patient's status, as described. 33 Laminin 511/521 (10 µg, Sigma-Aldrich) from human placenta was immobilized in uncoated µI 
Phosphorylation assays
RBCs and K562-Lu cells were phospholabeled as described. 33 Briefly, RBCs (200 µl) were incubated in 1.8 ml of buffer A (150 mM NaCl; 20 mM Tris-HCl, pH 7.5; 10 mM KCl; 1 mM 
Statistical analyses
Results are expressed as medians [interquartile range (IQR)], means ± SD, means ± s.e.m., numbers or percentages, as appropriate. Nonparametric tests were used because normal distribution could not be assumed because of the small samples (< 30) and those data had skewed distributions. Thus, quantitative parameters were compared between groups using a Mann- 
Results

Patients
The 49 homozygous SCD patients enrolled in this study formed 3 groups: 13 patients followed prospectively before and after starting HU (20 mg/kg/d), with 6 months of follow-up (pre-post group); 15 untreated patients (UT group); and 21 HU-treated patients (HU group). Results obtained with blood samples from the pre-post group before and > 6 months after starting HU were also included in the UT and HU groups, thereby raising the respective numbers of blood samples to 28 and 34. The mean ± SD age and the male/female ratio were 36 ± 8.34 years and 0.75 for the UT group and 32 ± 8.64 years and 0.41 for the HU group. RBCs from 7 healthy donors were also analyzed.
Less adhesion to laminin by SS RBCs from HU-treated patients
The effect of HU treatment on SS RBC adhesion to laminin was investigated with adhesion assays under flow conditions with 34 blood samples from HU-treated patients and 28 from UT patients.
HU-exposed SS RBCs adhered less than UT SS RBCs with respective medians of 40 vs 200
RBCs/mm² at 2 dyne/cm² (P = .007) ( Figure 1A ) and 160 vs 550 RBCs/mm² at 0.4 dyne/cm² (P = .008) (not shown). The impact of HU on cell adhesion was also analyzed by comparing the UT and HU groups in terms of RBC-adhesion value distributions. We found that the dispersion of values was much wider for the UT group than the HU group, with significantly different betweengroup variance values (Fisher's exact test, P < .0001). Adhesion of RBCs from 7 control donors was close to null and significantly lower than for the UT and HU groups (P < .01).
Because of wide interindividual variability in SCD, the same assays were run using blood samples from 13 pre-post group patients which showed that adhesion was significantly lower inserm-00821117, version 1 -7 May 2013 after 6 months of HU (P = .013), and dramatically diminished for the 5 patients with the highest adhesion levels before starting HU ( Figure 1B ).
SS RBC adhesion to laminin is not correlated with the Lu/BCAM expression level
To determine whether SS RBC adhesion to laminin was conditioned by the Lu/BCAM expression level, flow cytometry and cell-adhesion assays were conducted with 14 and 12 HU-and UT-group blood samples, respectively. When all patients were taken into account, no correlation was found Figure 4A , typical result). As expected, both isoforms were expressed on RBCs but only Lu gp was phosphorylated ( Figure 4A ). It is noteworthy that Lu phosphorylation decreased during HU treatment in this patient while no significant drop was observed for his percentage of circulating reticulocytes ( Figure 4A ).
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Decreased Lu-gp phosphorylation was observed after 15 days of HU for 3 patients and within 2 months for the 2 others. This reduction persisted throughout the 6 months of follow-up and was highly significant after 6 months of treatment (P = .005, n = 5 patients) ( Figure 
More adhesion to laminin of reticulocytes where Lu/BCAM phosphorylation mainly occurs
The SCD RBC lifespan is dramatically shortened and the corresponding reticulocyte count is much higher than in healthy controls. To determine whether the SS reticulocyte percentage could influence RBC adhesion to laminin, flow-adhesion assays were performed with reticulocyteenriched UT RBCs obtained after whole blood fractionation by Percoll double-density gradient centrifugation. The median percentage of reticulocytes in whole blood (W), the low-density reticulocyte-rich fraction (LDF) and the pellet (reticulocyte-poor fraction, PF) were 8.2, 53 and 4.8, respectively. The LDF exhibited the highest cell-adhesion level, adhering more than cells from whole blood (P < .01) and the pellet (P < .05) ( Figure 5A ). Because Lu/BCAM-mediated cell adhesion to laminin is modulated by phosphorylation, we analyzed Lu-isoform phosphorylation in both fractions and whole blood ( Figure 5B ). The phosphorylation level (P/WB ratio) was directly correlated to the percentage of reticulocytes ( Figure 5C , P < .0001, r² = 0.985, n = 5 patients), indicating that Lu-gp was phosphorylated mainly in young immature RBCs of UT patients.
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Considering these results we asked the question whether the decreased Lu/BCAM phosphorylation in HU-treated patients could be a consequence of the HU-driven decrease of circulating reticulocytes. To answer this question Lu/BCAM phosphorylation levels were determined in RBCs from 8 HU-treated patients and plotted against their percentage of reticulocytes ( Figure 5D ). As expected, low levels of Lu/BCAM phosphorylation were obtained for all patients. Interestingly, higher reticulocyte count was not associated with higher Lu/BCAM phosphorylation. Figure 5D shows that Lu/BCAM phosphorylation was independent of the reticulocyte percentage of HU-treated patients indicating that the decrease of Lu/BCAM phosphorylation in HU-treated patients was not a consequence of their decreased reticulocyte count.
HU exposure leads to less K562-Lu cell adhesion to laminin and less Lu-gp phosphorylation
In showing that HU could diminish cell adhesion to laminin by modulating Lu-gp phosphorylation.
Intracellular levels of cAMP are decreased under HU treatment
Two signaling pathways involved in enhanced Lu/BCAM-mediated SS RBC adhesion to laminin have been described: the PKA 30,33 and the Epac/Rap1 31 pathways. Because cAMP is a common upstream effector of both pathways, its intracellular levels were measured in SS RBCs. We first compared the basal levels of cAMP in SS versus AA RBCs and found higher levels in the former, as previously reported 30 ( Figure 7A ). We then wondered whether cAMP production could be modulated under HU treatment. Intracellular levels of cAMP were determined in RBC samples of 7 pre-post group patients and showed a steady and significant decrease over time ( Figure 7B , P = .002). The effect of HU on intracellular cAMP levels was also measured using K562-Lu cells the eNOS-cGMP pathway. [40] [41] [42] [43] HU could also prevent neutrophil activation and adhesion to fibronectin in a cAMP-PKA-dependent manner. 44, 45 The in vivo effect of HU on Lu/BCAM longisoform phosphorylation and cAMP decrease could not be tested ex vivo using SS RBCs because of hemolysis. Nevertheless, using human erythroleukemic K562-Lu cells expressing recombinant Lu gp, we showed that the ex vivo effects of HU were similar to those observed for SS RBCs from HU-treated SCD patients. Although the K562 cell line derives from an erythroid lineage it could not be compared to RBCs. Nevertheless, these experiments revealed that HU could negatively impact cAMP levels, Lu/BCAM phosphorylation and cell adhesion to laminin in this cell line suggesting that it could help deciphering the HU mechanism of action.
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Another new finding was the correlation between Lu-gp phosphorylation and the percentage of reticulocytes in UT patients, which could explain why their reticulocyte-enriched fractions adhered more to laminin than mature RBCs. Two studies investigated SS RBC adhesion to laminin according to their density and reported that cells from the dense fraction were the most adherent. 46, 47 Our results were obtained using a different experimental approach to have reticulocyte-enriched fractions. The 5-10% of very dense and irreversibly sickled cells, reported to be the most adherent, 46, 47 were diluted in our pellet fraction with cells of intermediate density known to be much less adherent. We chose to focus on reticulocytes, because no Lu/BCAM phosphorylation was detected in mature dense RBCs and our objective was to determine the effect of HU on Lu/BCAM activation through the phosphorylation of the long Lu isoform. Our results
showed that, contrary to what was observed for UT patients, the Lu/BCAM phosphorylation level was independent of the reticulocyte count in HU-treated patients, as patients with < 3% and > 7% of reticulocytes showed similar phosphorylation levels ( Figure 5D ). We showed that the HU effect on RBC adhesion preceded the reticulocyte count decline. Pre-post group RBC adhesion to laminin was often diminished before the reticulocyte count changed significantly, revealing a qualitative modification of the adhesive properties of circulating reticulocytes. This was clearly demonstrated for the patient in figure 4A who showed a dramatic decrease of Lu/BCAM phosphorylation after > 6 months of HU therapy while no significant change was observed for his percentage of circulating reticulocytes. In addition, the reticulocyte-count diminution under HU in the 5 pre-post group patients was not statistically significant (P = .26). Nevertheless, because the phosphorylation level results from the balance between kinase and phosphatase activities, and the RBC stock of kinases declines with age, it cannot be excluded that the prolongation of RBC survival under HU could partially contribute to the reduced Lu/BCAM phosphorylation.
In addition to phosphorylation, Lu/BCAM-mediated cell adhesion to laminin is regulated by the interaction of the Lu/BCAM cytoplasmic domain with the spectrin-based skeleton. [48] [49] [50] Loss of interaction with spectrin increases Lu/BCAM-mediated cell adhesion to laminin. 
